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To The Editor,  
 
We have prepared a letter for the Journal of Infection which we feel is of interest to many of 
your readers and is particularly timely. 
 
It details our early experience of using a dual target (RdRp and E gene) real time PCR assay. 
As initial diagnostic algorithms for SARS-CoV-2 raised concerns of the specificity of E gene 
amplification in isolation due to batch contamination of reagents, we were interested in 
particular in analysing the samples where E gene amplified in the absence of RdRp 
amplification. 
 
The principle findings are that E gene detection in the absence of RdRp detection was 
common (12.3%) amongst positive samples, the majority (96.9%) of which were considered 
true positives following further assessment. In addition, in a subset of samples where 
symptom onset was available (145 samples from 128 patients), it was clear that the cycle 
threshold values for both RdRp and E gene were lowest around 48  ? 72 hours following 
symptom onset (Figure 2), and at each stage of infection the median CT values for RdRp 
were higher than those for the E gene. 
 
We believe dual target testing, using the E gene as a second target, will help improve both 
laboratory diagnostic pick up and our clinical response to this pandemic. This may be 
particularly relevant due to the current difficulty in sourcing nucleic acid extraction kits 
globally, as alternative options such as PCR without a nucleic acid extraction step are being 
explored, which inherently reduces the sensitivity of RNA detection from clinical samples 
&RYHU/HWWHU
 Many thanks for your consideration. 
 
Dr Hayley Colton & Dr Michael Ankcorn 
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Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2 1 
infection: Experience at a large NHS Foundation Trust in the UK 2 
Dear Editor, 3 
We read with interest the letter from Hao et al highlighting the issues regarding the 4 
sensitivity of real time reverse-transcriptase polymerase chain reaction (RT-PCR) testing of upper 5 
respiratory tract samples for COVID19 disease [1]. Extensive RT-PCR testing by has been key to 6 
clinical decision-making, epidemiological analysis and policy development during the current severe 7 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The majority of RT-PCR assays 8 
target the RNA-dependent RNA polymerase (RdRp), envelope protein (E) or nucleocapsid protein (N) 9 
genes [2]. However, initial testing algorithms and expert opinion from the European Centre for 10 
Disease Prevention and Control (ECDC) advised that E gene amplification in isolation should be 11 
treated cautiously, due to concerns of non-specificity and issues related to contamination of 12 
reagents [3].  Early experience at Sheffield Teaching Hospitals NHS Foundation Trust (UK) on serially 13 
sampled patients with confirmed SARS-CoV-2 infection suggested that E gene detection persists 14 
beyond RdRp detection, and may offer enhanced diagnostic sensitivity. Therefore we explored the 15 
significance of E gene detection in relation to RdRp, and in the absence of RdRp detection in a 16 
retrospective evaluation of SARS-CoV-2 RT-PCR testing.  17 
A total of 12,015 clinical samples (combined nose/throat swabs or lower respiratory tract samples) 18 
were tested for SARS-CoV-2 as part of routine clinical diagnostics between 2nd March 2020 and 5th 19 
April 2020 at Sheffield Teaching Hospitals NHS Foundation Trust. Samples were extracted on the 20 
MagnaPure96 platform (Roche Diagnostics Ltd, Burgess Hill, UK). SARS-CoV-2 RNA was detected on 21 
6µl of extract using a dual target (E gene and the RdRp gene) in-house PCR on ABI Thermal Cycler 22 
(Applied Biosystems, Foster City, United States) (supplementary material) [4]. The assay was 23 
modified to a multiplex single-well assay with the addition of PCR primers to detect a housekeeping 24 
gene, Ribonuclease P (RNAse P), which acts as an internal control and to assess sample quality.  25 
0DQXVFULSW &OLFNKHUHWRYLHZOLQNHG5HIHUHQFHV
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Of the samples tested, 2,593 samples (21.6%) were positive with amplification curves for one or 26 
both target genes. Amongst positive results, we found E gene amplification alone to be common (n= 27 
319, 12.3%), although the majority were positive for both RdRp and E gene targets (n = 2273, 87.7 %) 28 
and only 1 sample (<0.1 %) had RdRp gene amplification alone.  29 
From the E-only positive group (n=319), 69 (21.6%) samples had low level amplification in the E gene 30 
(cycle threshold (CT) A? ? ? ? ĂŶĚ ǁĞƌĞ ŝŶǀĞƐƚŝŐĂƚĞĚ ĨƵƌƚŚĞƌ ?Within this subset, the majority (n=59, 31 
85.5%) were considered to be true positives because they were either a) confirmed by an alternative 32 
assay (n=48) or b) a preceding or subsequent sample was positive for both E and RdRp (n=11) (Table 33 
1). The alternative assay employed was a modified version of the Centers for Disease Control and 34 
Prevention (CDC) assay targeting the N gene (Micropathology Ltd, Coventry, UK) in most cases 35 
(n=47) or an alternative RdRp assay (n=1)  [7]. Six samples (8.7 %) could not be confirmed in an 36 
alternative assay which ŚĂĚĞŝƚŚĞƌŚŝŐŚdǀĂůƵĞƐĨŽƌƚŚĞŐĞŶĞ ?ŶA? ? ?dǀĂůƵĞƐA? ? ? ? ? ?ŽƌŚĂĚŐŽŽĚ37 
amplification curves not reaching the threshold (n=2). To further confirm the presence of SARS-CoV-38 
2 RNA in samples with E gene only amplification, 11 samples were selected and successfully 39 
underwent whole genome sequencing (supplementary material). Analysis of the RdRp primer or 40 
probe binding sites in these samples did not reveal any mismatches to explain the lack of RdRp RT-41 
PCR positivity (supplementary material). 42 
We further explored the relationship between E gene detection and RdRp gene detection. Amongst 43 
samples with both RdRp gene and E gene amplification (n= 2273) , we found that CT values for the E 44 
gene target were significantly lower than the CT values for RdRP, with a mean difference of 5.8 45 
(Paired t test, p-value < 2.2e-16, 95% CI 5.79-5.92) (supplementary material). In a subset of samples 46 
where symptom onset was available (145 samples from 128 patients), it was clear that the CT values 47 
for both RdRp and E gene were lowest around 48  ? 72 hours following symptom onset (Figure 1). At 48 
each stage of infection, the median CT values for RdRp were higher than those for the E gene. 49 
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By using the E gene target in addition to the RdRp gene target we observed a significantly increased 50 
diagnostic pick up (11.9%). In one patient, E gene amplification was detected for three days beyond 51 
RdRp amplification, indicating a possible widening of the diagnostic window. Our findings confirm 52 
that clinical samples with E only amplification should not be dismissed as non-specific results. Not 53 
only were we able to obtain whole genome sequences for SARS-CoV-2 from a subset of this group, 54 
we also found that 85% of E only samples with high CT values were confirmed by a second assay 55 
targeting the N gene or an alternative RdRp only assay. 56 
The enhanced sensitivity seen for the E gene in our dual target E-RdRP assay is yet to be explained. 57 
We observed a mean difference of over five CT values when comparing E gene to RdRp values, which 58 
may suggest the possibility of higher copy numbers of E gene being present in the primary or 59 
ĞǆƚƌĂĐƚĞĚƐĂŵƉůĞ ?ƵĞƚŽƚŚĞƵŶŝƋƵĞƚƌĂŶƐĐƌŝƉƚŝŽŶƐƚƌĂƚĞŐǇŽĨĐŽƌŽŶĂǀŝƌƵƐĞƐ ?ŐĞŶĞƐƚŽǁĂƌĚƐƚŚĞ  ? ?60 
end of the genome would be present in higher copy numbers during active viral replication, which 61 
could explain these findings [5]. It is also possible that PCR optimised conditions in a multiplex 62 
system favours E gene amplification, however we found no significant loss of RdRp detection when 63 
comparing single and multiplex systems during validation, with observed CT rises averaging 1-2 64 
cycles (data not shown). In addition, we found no evidence of primer or probe mismatches in the 65 
RdRp region. 66 
We believe dual target testing, using the E gene as a second target, will help improve both diagnostic 67 
sensitivity and the appropriate clinical response to this pandemic. We urge testing laboratories to 68 
carefully consider the use of the E gene as a target in order to optimise SARS-CoV-2 diagnostics, 69 
including strategies to confirm samples with E gene only amplification as we have described. 70 
Word count 996  71 
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Tables & Figures 106 
  107 
 108 
 109 
 n % 
Sent for confirmation at reference laboratoryࡏ 54 78.26 
- Confirmed by alternative assay 48 (88.89) 
- Not confirmed 6 (11.11) 
Repeat clinical sample positive 5 7.25 
Previous clinical samples positiveʗ 6 8.70 
Resulted without further testingۥ 4 5.80 
Total  69 
  110 
 111 
Table 1. Summary of samples with low level E gene ĂŵƉůŝĨŝĐĂƚŝŽŶĂůŽŶĞ ?dA? ? ? ? ? CT, cycle threshold; 112 
E, envelope gene. 113 
 114 
ࡏ Most samples (n=53) were tested at Micropathology Ltd (Coventry) using a SARS-CoV-2 N gene 115 
assay using a modified CDC assay[6]. The other sample confirmed positive at PHE Colindale using an 116 
alternative SARS-CoV-2 RdRp assay. 117 
ɎƐƉĂƌƚŽĨƚŚĞ,ŝŐŚŽŶƐĞƋƵĞŶĐĞƐ/ŶĨectious Diseases network, Sheffield received some of the first 118 
positive patients in the United Kingdom, who had daily swabs taken. E gene amplification appeared 119 
to persist in this cohort after the RdRp became negative. 120 
ۥ &ŽƵƌ ƌĞƐƵůƚƐ ǁĞƌĞ ĂƵƚŚŽƌŝƐĞĚ ǁŝƚŚŽƵt further testing due to high pre-test probability e.g. 121 
compatible symptoms with a confirmed household exposure to SARS-CoV-2. 122 
 123 
 124 
 125 
 126 
  127 
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 128 
 129 
Figure 1. E and RdRp gene cycle threshold results in relation to symptom onset. E and RdRp 130 
amplification results plotted against days of symptom onset in 145 samples from 128 patients. 131 
Lowest CT values were seen around day 3 of symptoms, with mean RdRp CT higher at a given day 132 
compared to E gene CT value. The lines represent the smoothed conditional mean with 95% 133 
confidence intervals in the grey bars. E, envelope gene; RdRp, RNA-dependent RNA-polymerase. 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
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Supplementary Material 148 
 149 
 150 
 151 
 152 
 153 
 154 
 155 
 156 
 157 
 158 
 159 
 160 
 161 
 162 
 163 
 164 
 165 
 166 
 167 
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Table S1. Primer and Probe sequences used for RdRp and E gene detection. 170 
Name Sequence 
RdRp gene F GTG TGA RAT GGT CAT GTG TGG CGG 
RdRp gene R CAR ATG TTA AAS ACA CTA TTA GCA TA 
RdRp gene P 6-FAM- CAG GTG GAA CCT CAT CAG GAG ATG C- BHQ1 
E gene F ACA GGT ACG TTA ATA GTT AAT AGC GT 
E gene R ATA TTG CAG CAG TAC GCA CAC A 
E gene P HEX-ACA CTA GCC ATC CTT ACT GCG CTT CG-BHQ1 
 171 
Abbreviations: BHQ-1, black hole quencher; F, forward primer; HEX, HEX flourophore; P, probe; R, 172 
reverse primer; 6-FAM, 6-Carboxyfluorescein flourophore. 173 
 174 
 175 
 176 
 177 
 178 
 179 
 180 
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 182 
Initial Result N  % 
 
Both RdRp+ and E+ 
 
 
2273 
 
18.92 
 
RdRp- and E+ 
 
 
319 
 
2.66 
 
RdRp+ and E- 
 
 
1 
 
<0.01 
 
Invalid (negative internal control) 
 
 
8 
 
0.07 
 
RdRp- and E- 
 
 
9414 
 
78.35 
Total 12015 
 183 
 184 
Table S2. Summary results for all diagnostic samples tested for SARS-CoV-2. A total of 12,015 185 
clinical samples (combined nose and throat swabs or lower respiratory tract specimens) were tested 186 
for SARS-CoV-2 by PCR as part of routine clinical diagnosis over a period of approximately four 187 
weeks. The results are summarised above. RdRp, RNA-dependent RNA-polymerase gene; E, 188 
envelope gene. 189 
 190 
  191 
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Table S3. Whole Genome Sequencing of Samples with Unamplified RdRp 192 
 193 
GISAID Identifier 
E gene 
CT 
RdRp 
gene 
CT 
Coverage 
across 
genome 
ARTIC 
Primer set 
hCoV-19/England/SHEF-C0488/2020 31.2 NA 0.988 V3 
hCoV-19/England/SHEF-BFD09/2020 32.2 NA 0.965 V2 
hCoV-19/England/SHEF-BFF30/2020 32.3 NA 0.959 V1 
Not Submitted Due To Low Coverage 34.7 NA 0.791 V3 
hCoV-19/England/SHEF-C0567/2020 34 NA 0.946 V3 
hCoV-19/England/SHEF-C05D0/2020 33.9 NA 0.995 V3 
hCoV-19/England/SHEF-BFECA/2020 33.5 NA 0.885 V1 
hCoV-19/England/SHEF-BFF5E/2020 31.7 NA 0.962 V1 
hCoV-19/England/SHEF-C01DC/2020 34.6 NA 0.944 V1 
hCoV-19/England/SHEF-BFE51/2020 32.4 NA 0.988 V1 
hCoV-19/England/SHEF-BFCA2/2020 32.9 NA 0.988 V1 
 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
12 
 
 206 
 207 
 208 
 209 
 210 
Figure S1. Boxplot of E gene CT values and RdRp CT values in samples with PCR amplification 211 
curves for both targets. The box is defined by the interquartile range and the median value is 212 
represented by the central horizontal line. CT values for the E gene target were significantly lower 213 
than the CT values for RdRP, with a mean difference of 5.8 (Paired t test, p-value < 2.2e-16, 95% CI 214 
5.79-5.92). CT, cycle threshold; RdRp, RNA-dependent RNA-polymerase gene; E, envelope gene. 215 
 216 
  217 
p = < 2.2e-16 
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 218 
 219 
 220 
Figure S2. Correlation of E and N gene cycle thresholds. A total of 53 extracts were sent to another laboratory 221 
(Micropathology Ltd, Coventry) for confirmatory testing in an N gene assay. Forty seven samples were 222 
confirmed as harbouring SARS-CoV-2 RNA with N gene amplification, 46 of which are plotted above. No 223 
significant correlation was seen between the CT values for the E gene and the confirmatory N gene assay 224 
(Pearson correlation 0.15, p = 0.3).  225 
Abbreviations: CT, cycle threshold; RdRp, RNA-dependent RNA-polymerase gene; E, envelope gene. 226 
  227 
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 228 
 229 
 230 
Figure S3. Multiple Sequence Alignment of SARS-CoV-2 Consensus Sequences. 11 samples reactive 231 
for E and not the RdRp gene were subjected to Oxford Nanopore sequencing using the artic network 232 
protocol1 to determine variation that may be present in the RdRp primer or probe sites that could 233 
lead to a failure of the assay. A multiple sequence alignment was carried out for the resulting 234 
consensus sequence for these samples using MAFFT (v7.450) (1) including the Wuhan-Hu-1 235 
(MN908947.3) reference sequence. Numbers represent position in genome. There was no sequence 236 
variation present in either primer site or the probe. Figure was produced using Jalview (2). 237 
  238 
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